The cost and complexity of clinical trials have increased drastically in recent years. Despite technological advancements, there has been a dip in clinical trial process efficiency. Traditional monitoring process not only accounts for a larger percentage of clinical trial cost, but it may also lead to data quality/integrity issues like frauds, fabrication, and other transcription-based errors.

The increased number of FDA’s Warning Letters on trial monitoring, majorly for non-compliance to GCP and/or Protocol, along with lack of promptness to rectify the insufficiencies identified through monitoring, has justified the need for guidelines on RBM.

DOWNLOAD THE WHITEPAPER

The cost and complexity of clinical trials have increased drastically in recent years. Despite technological advancements, there has been a dip in clinical trial process efficiency. Traditional monitoring process not only accounts for a larger percentage of clinical trial cost, but it may also lead to data quality/integrity issues like frauds, fabrication, and other transcription-based errors.

The increased number of FDA’s Warning Letters on trial monitoring, majorly for non-compliance to GCP and/or Protocol, along with lack of promptness to rectify the insufficiencies identified through monitoring, has justified the need for guidelines on RBM.